1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer

This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1 yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5 bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-...

Full description

Saved in:
Bibliographic Details
Main Authors Bilic, Sanela, Cameron, John Scott, Juan, Alberto, Julio, Cesar, Camacho, Gomez, Castro-Palomino, Laria, Howard Jr., Danny Roland
Format Patent
LanguageEnglish
Published 12.11.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1 yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5 bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.
Bibliography:Application Number: AU20200256467